Oxidized MIF is an Alzheimer’s Disease drug target relaying external risk factors to tau pathology

Andreas Müller-Schiffmann, Felix Torres, Anatolly Kitaygorodskyy,Anand Ramani, Argyro Alatza, Sarah K. Tschirner,Ingrid Prikulis, Shaofeng Yu, Debendranath Dey, Suguna Mallesh, Dharma Prasad,Dennis Solas,Verian Bader,Annemieke Rozemuller,Selina Wray,Jay Gopalakrishnan,Roland Riek,Vishwanath R. Lingappa,Carsten Korth

crossref(2021)

引用 0|浏览0
暂无评分
摘要
SummaryThe viral life cycle usurps host cellular factors, redirecting them from physiological functions to viral needs thereby revealing their “moonlighting” functions, disturbing cellular proteostasis, and increasing risk of specific, virus-associated protein misfolding diseases (PMD). Identifying such virus-repurposed host proteins therefore allow study of fundamental cellular events leading to associated “sporadic” PMD. Here, we identified a small molecule with unprecedented activity against neurotropic herpes simplex virus 1 (HSV-1) modulating an allosteric site of Macrophage Migration Inhibitory Factor (MIF). The compound efficiently reduced HSV-1-mediated tau phosphorylation or aggregationin vitroandin vivo, even without HSV-1 infection. The lead compound specifically interacted with an oxidized conformer of MIF (oxMIF) from either recombinant MIF orpost-mortembrain homogenates of patients with Alzheimer’s disease (AD). OxMIF thus participates in a host-viral interface connecting HSV-1 infection, and possibly other external stressors, with tau cellular pathology characteristic for PMD, including Alzheime’s disease.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要